Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
human GPR35
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "human GPR35" in MCE Product Catalog:
3
Target:
Research Areas:
Zaprinast (M&B 22948) is a selective inhibitor of cGMP-selective Phosphodiesterase (PDE5). Zaprinast causes a significant increase in cGMP levels in myocytes. Zaprinast is a G protein-coupled receptor 35 (GPR35) agonist which activates rat GPR35 strongly and activates human GPR35 moderately. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects .
2
2 Cited Publications
Research Areas:
ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM) . ML 145 has no significant activity for GPR35 at either rodent ortholog .
Target:
Research Areas:
Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β-arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide .
Cat. No.: HY-RS05705
Target:
Research Areas:
GPR35 Human Pre-designed siRNA Set A contains three designed siRNAs for GPR35 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
GPR35 agonist 4 (compound 10) is a potent GPR35 agonist with an pEC50 of 5.86. GPR35 agonist 4 shows high potency human and rat GPR35. Mutation of arginine 3.36 eliminates agonist function of GPR35 agonist 4 .
Cat. No.: HY-169302
CAS No.: 2855918-34-0
GPR35 activator-1 (example 5) is a potent GPR35 activator with a Ki of 0.08 nM for human GPR35 .
Cat. No.: HY-169301
CAS No.: 2994189-01-2
Gpr35 modulator 1 (compound 1-18) is a potent modulator of Gpr35, with the IC50 of ≤ 100 nM in HEK293 cells stably transfected with human GPR35 .
Cat. No.: HY-167706
CAS No.: 53882-13-6
Target:
Research Areas:
Diethyl-Lodoxamide is a highly potent GPR35 agonist with potential to inhibit inflammatory bowel disease. Diethyl-Lodoxamide activates GPR35 in humans, mice and rats, showing similar EC50 values. Diethyl-Lodoxamide can alleviate the clinical symptoms of DSS-induced inflammatory bowel disease in mouse models, and the effect is better than the traditional drug 5-ASA. The pharmaceutical properties of Diethyl-Lodoxamide have been optimized to better meet the requirements of drug design .
Cat. No.: HY-W1058476
CAS No.: 1443367-20-1
Research Areas:
GPR35 agonist 6 is a potent and selective agonist targeting GPR35, with an EC50 of 12.1 nM against human GPR35. GPR35 agonist 6 activates the human splice variant GPR35b with comparable efficacy, showing an EC50 of 22.1 nM. GPR35 agonist 6 also exhibits weak GPR55 antagonistic activity, with an IC50 of 21.7 μM, and its agonistic activity towards GPR35 is significantly stronger than its antagonistic activity towards GPR55. GPR35 agonist 6 initiates GPR35 downstream signaling by inducing β-arrestin recruitment. GPR35 agonist 6 is used to investigate GPR35-mediated diseases, such as gastrointestinal lesions and gastric cancer .
Cat. No.: HY-187385
Target:
Research Areas:
GPR35 agonist 8 is a cross-species, highly potent GPR35 agonist (human EC50: 12 nM; murine EC50: 2 nM). GPR35 agonist 8 reduces lipid accumulation, ameliorates lipid metabolism disorders, alleviates hepatic inflammation and liver fibrosis, and relieves hepatic steatosis. GPR35 agonist 8 can be used for research on metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis .
Cat. No.: HY-107536R
CAS No.: 1164500-72-4
Target:
Research Areas:
ML 145 (Standard) is the analytical standard of ML 145 (HY-107536). This product is intended for research and analytical applications. ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. ML 145 has over 1000-fold more selective for GPR35 compared to GPR55 (IC50/EC50=21.7 μM) . ML 145 has no significant activity for GPR35 at either rodent ortholog .
Cat. No.: HY-P702306
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: GPR35; Kynurenic Acid Receptor; G Protein-Coupled Receptor 35; KYNA Receptor; G-Protein Coupled Receptor 35
Species:
Human
Source:
E. coli Cell-free
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
